HEK293-Based Production Platform for γ-Retroviral (Self-Inactivating) Vectors: Application for Safe and Efficient Transfer ofCOL7A1cDNA-Reference-Cited by-同舟云学术

HEK293-Based Production Platform for γ-Retroviral (Self-Inactivating) Vectors: Application for Safe and Efficient Transfer ofCOL7A1cDNA

Published:2014-12 Issue:4 Volume:25 Page:218-228
ISSN:2324-8637
Container-title:Human Gene Therapy Clinical Development
language:en
Short-container-title:Human Gene Therapy Clinical Development

Author:

Hennig Katharina¹,Raasch Lars¹,Kolbe Carolin¹,Weidner Sibylle¹,Leisegang Matthias²,Uckert Wolfgang²³,Titeux Matthias⁴⁵,Hovnanian Alain⁴⁵⁶,Kuehlcke Klaus¹,Loew Rainer¹

Affiliation:

1. EUFETS GmbH, 55743 Idar-Oberstein, Germany.

2. Max-Delbrück Center for Molecular Medicine, 13092 Berlin, Germany.

3. Institute of Biology, Humboldt University Berlin, 13092 Berlin, Germany.

4. INSERM UMR 1163, Laboratory of Genetic Skin Diseases: From Disease Mechanism to Therapies, 75730 Paris, France.

5. Imagine Institute, Paris Descartes–Sorbonne Paris Cité University, 75730 Paris, France.

6. Department of Genetics, Necker Hospital, 75730 Paris, France.

Publisher

Mary Ann Liebert Inc

Subject

Genetics(clinical)

Link

http://www.liebertpub.com/doi/pdf/10.1089/humc.2014.083

Reference50 articles.

1. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

2. Side effects of retroviral gene transfer into hematopoietic stem cells

3. Divergent picornavirus IRES elements

4. Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity

5. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EBAG9 silencing exerts an immune checkpoint function without aggravating adverse effects;Molecular Therapy;2022-11

2. Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages;Molecular Therapy - Methods & Clinical Development;2022-03

3. Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy;Human Gene Therapy;2021-09-01

4. Generation of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells;Molecular Therapy - Methods & Clinical Development;2019-09

5. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma;Molecular Therapy;2018-08